Handa Pharmaceuticals wins FDA tentative approval for HND-039 ahead of Aug. 14 patent expiry
The 505(b)(2) cancer drug candidate now moves to final approval preparations, with Handa targeting a U.S. launch soon after patent restrictions on the reference drug are lifted.